« Zurück
Startseite /
Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E9) - HRP - 50 µg

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E9) - HRP - 50 µg

ArtNr	LEIN-LT7017-50ug
Hersteller	Leinco Technologies
Menge	50 ug
Kategorie	Antibodies ELISA Primary Antibodies Immunostaining
Typ	Antibody Monoclonal
Applikationen	ELISA
Clon	NP1-E9
Specific against	Virus, SARS-CoV-2
Host	Mouse
NCBI	43740575
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Quality Tested by Leinco ELISA
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases\|Monoclonal Antibodies\|Recombinant Antibodies\|SARS-CoV-2
Manufacturer - Targets	SARS-CoV-2 Nucleocapsid (N)
Country of Origin	USA
Shipping Temperature	Ships Overnight on Blue Ice
Storage Conditions	This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Product Description	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8, 9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic.
Background	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family ¹. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) ². The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively ^{3, 4}. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex ⁵. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways ^{6, 7}. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein ⁸. It is also immunogenic, and antibodies ^{8, 9} and memory T cells ^{10, 11} targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 ¹². The N protein also contributes to immune evasion by antagonizing antiviral RNAi ¹³, suggesting its potential value as a targeted therapeutic.
PubMed	SARS-CoV-2 Nucleocapsid (N)
Manufacturer - Research Area	COVID-19, Infectious Disease, Seasonal and Respiratory Infections, Viral, IVD Raw Material
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	Anti-SARS-CoV-2 Nucleocapsid, clone NP1-E9, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein.
RRID	AB_2893985
Concentration	0.5 mg/ml
Formulation	This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Antigen Distribution	The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Immunogen	SARS-CoV-2 Nucleocapsid (N) Protein
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, Monoclonal Antibody, COVID-19

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-LT7017-50ug-safety-datasheet.pdf